Drug intelligence / Profile preview

VRC-EBOADV018-00-VP

Development stage: Phase 1
Lead developer: Vaccine Research Center
Modality: Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

VRC-EBOADV018-00-VP is a recombinant adenovirus serotype 5 (rAd5) vector vaccine designed to prevent Ebola virus infection. It encodes for the glycoprotein of the Ebola virus, aiming to stimulate an immune response without causing the disease itself. The vaccine is administered as a single injection and is developed by the Vaccine Research Center (VRC) and Crucell.

Other names: Ebola virus vaccine - Crucell/Vaccine Research Center

Targets

Zaire ebolavirus glycoprotein

Beyond the preview

Go deeper on VRC-EBOADV018-00-VP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRC-EBOADV018-00-VP.

Explore the full profile